Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU

Jasper Therapeutics, Inc.

11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.
Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.
Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.
No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.
Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.